https://scholars.lib.ntu.edu.tw/handle/123456789/426641
標題: | Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan | 作者: | Wang, CK MING-CHIH HO Su C.-W. Wang T.-E. Dai C.-Y. CHIEN-HUNG CHEN Chen R.-C. Yang S.-S. Hung C.-F. Huang S.-F. Liao L.-Y. Huo T.-I. Wu C.-C. PO-HUANG LEE Ting C.-T. Lee W.-C. Chau G.-Y. Wang C.-C. Lee K.-T. Huang Y.-H. Lin S.-M. GUAN-TARN HUANG Chen K.-Y. Lin X.-Z. Hwang J.-I. Chiou Y.-Y. Wang C.-K. Hu J.-T. Chen S.-C. PO-CHIN LIANG Lee R.-C. Wu D.-K. Lin C.-Y. Lin C.-C. ANN-LII CHENG CHIUN HSU Chao Y. Chen L.-T. Wang P.-M. Wang P.-M. Hong J.-H. Hsu H.-C. Chen S.-W. Leung S.W. CHIA-HSIEN CHENG Wu J.-C. Wu C.-Y. Hsu Y.-C. Hsu C.-W. YEN-HSUAN NI Lin C.-L. Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group Surveillance group Diagnosis group Staging group Surgery group TACE/TARE/HAI group Target therapy/systemic therapy group Radiotherapy group Prevention group Drafting group |
關鍵字: | Diagnosis; Hepatocellular carcinoma; Staging; Surveillance; Treatment | 公開日期: | 五月-2018 | 出版社: | ELSEVIER TAIWAN | 卷: | 117 | 期: | 5 | 起(迄)頁: | 381 | 來源出版物: | Journal of the Formosan Medical Association = Taiwan yi zhi | 摘要: | Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality in Taiwan. To help clinical physicians to manage patients with HCC, the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan produced the management consensus guideline for HCC. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/426641 | ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2017.09.007 | SDG/關鍵字: | alpha fetoprotein; antivirus agent; cancer vaccine; cytotoxic agent; gadoxetic acid; illicit drug; interferon; new drug; nonnucleoside reverse transcriptase inhibitor; RNA directed DNA polymerase inhibitor; sorafenib; tumor marker; yttrium 90; advanced cancer; antiviral therapy; Article; ascites; cancer chemotherapy; cancer control; cancer diagnosis; cancer epidemiology; cancer immunization; cancer incidence; cancer patient; cancer prevention; cancer prognosis; cancer radiotherapy; cancer recurrence; cancer staging; cancer surgery; chemoembolization; Child Pugh score; chronic hepatitis B; chronic hepatitis C; computer assisted tomography; consensus; echography; evidence based practice; external beam radiotherapy; Hepatitis B virus; Hepatitis C virus; high risk patient; histopathology; human; liver biopsy; liver cell carcinoma; liver cirrhosis; liver function; medical society; meta analysis (topic); microwave thermotherapy; multicenter study (topic); multidetector computed tomography; national health insurance; nuclear magnetic resonance imaging; pleura effusion; portal vein thrombosis; practice guideline; radioembolization; radiofrequency ablation; randomized controlled trial (topic); risk reduction; systemic therapy; Taiwan; tertiary prevention; tumor ablation; tumor biopsy; tumor vascularization; tumor volume; virus replication; virus transmission; complication; consensus; gastroenterology; hepatitis B; hepatitis C; liver cell carcinoma; liver tumor; Carcinoma, Hepatocellular; Consensus; Gastroenterology; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Practice Guidelines as Topic; Societies, Medical; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。